BR112018011656A2 - derivados de hexahidropirzinotriazinona como inibidores de quinase - Google Patents

derivados de hexahidropirzinotriazinona como inibidores de quinase

Info

Publication number
BR112018011656A2
BR112018011656A2 BR112018011656A BR112018011656A BR112018011656A2 BR 112018011656 A2 BR112018011656 A2 BR 112018011656A2 BR 112018011656 A BR112018011656 A BR 112018011656A BR 112018011656 A BR112018011656 A BR 112018011656A BR 112018011656 A2 BR112018011656 A2 BR 112018011656A2
Authority
BR
Brazil
Prior art keywords
derivatives
hexahydropyrzinotriazinone
kinase inhibitors
hexahydropyrazine
oncologic
Prior art date
Application number
BR112018011656A
Other languages
English (en)
Inventor
Tracey Horsley Helen
Thomas Reuberson James
Charlotte Neuss Judi
John Mears Richard
Original Assignee
Katholieke Univ Leuven K U Leuven R&D
Ucb Biopharma Sprl
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Katholieke Univ Leuven K U Leuven R&D, Ucb Biopharma Sprl filed Critical Katholieke Univ Leuven K U Leuven R&D
Publication of BR112018011656A2 publication Critical patent/BR112018011656A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A61P33/06—Antimalarials
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Transplantation (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

Abstract

uma série de derivados de 1,2,6,7,9,9a- hexa-hidropirazino [ 1, 2 - d] [1,2,4] triazin-4-ona substituídos na posição 8 por um grupo heteroaromático bicíclico substituído opcionalmente fundido, e na posição 3 por uma variedade de grupos funcionais, que são inibidores seletivos da atividade de fosfatidilinositol-4-quinase iii (pi4kiiibeta), são benéficos no tratamento e / ou prevenção de várias doenças humanas, incluindo desordens inflamatórias, auto-imunes e oncológicas; doenças virais e malária; e rejeição de transplante de órgãos e células.
BR112018011656A 2015-12-10 2016-12-08 derivados de hexahidropirzinotriazinona como inibidores de quinase BR112018011656A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB1521767.2A GB201521767D0 (en) 2015-12-10 2015-12-10 Therapeutic agents
PCT/EP2016/080168 WO2017097871A1 (en) 2015-12-10 2016-12-08 Hexahydropyrazinotriazinone derivatives as kinase inhibitors

Publications (1)

Publication Number Publication Date
BR112018011656A2 true BR112018011656A2 (pt) 2018-12-04

Family

ID=55274503

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112018011656A BR112018011656A2 (pt) 2015-12-10 2016-12-08 derivados de hexahidropirzinotriazinona como inibidores de quinase

Country Status (10)

Country Link
US (1) US10450320B2 (pt)
EP (1) EP3386984B1 (pt)
JP (1) JP6775019B2 (pt)
CN (1) CN108699064B (pt)
BR (1) BR112018011656A2 (pt)
CA (1) CA3007975A1 (pt)
EA (1) EA037559B1 (pt)
ES (1) ES2894680T3 (pt)
GB (1) GB201521767D0 (pt)
WO (1) WO2017097871A1 (pt)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2019324089B2 (en) 2018-08-21 2024-06-13 Kyorin Pharmaceutical Co., Ltd. Bicyclic heteroaromatic ring derivative
US11168093B2 (en) 2018-12-21 2021-11-09 Celgene Corporation Thienopyridine inhibitors of RIPK2

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010103130A2 (en) 2009-03-13 2010-09-16 Katholieke Universiteit Leuven, K.U.Leuven R&D Novel bicyclic heterocycles
WO2010118207A1 (en) * 2009-04-09 2010-10-14 Schering Corporation Pyrazolo [1, 5-a] pyrimidine derivatives as mtor inhibitors
GB201012889D0 (en) 2010-08-02 2010-09-15 Univ Leuven Kath Antiviral activity of novel bicyclic heterocycles
GB201015411D0 (en) 2010-09-15 2010-10-27 Univ Leuven Kath Anti-cancer activity of novel bicyclic heterocycles
GB201114212D0 (en) 2011-08-18 2011-10-05 Ucb Pharma Sa Therapeutic agents
GB201115665D0 (en) 2011-09-09 2011-10-26 Univ Leuven Kath Autoimmune and inflammatory disorder therapy
GB201119401D0 (en) * 2011-11-10 2011-12-21 Ucb Pharma Sa Therapeutic agents
GB201217704D0 (en) 2012-10-03 2012-11-14 Ucb Pharma Sa Therapeutic agents
WO2014096423A1 (en) 2012-12-20 2014-06-26 Ucb Pharma S.A. Therapeutically active pyrazolo-pyrimidine derivatives
GB201410816D0 (en) 2014-06-17 2014-07-30 Ucb Biopharma Sprl And Katholieke Universiteit Leuven Therapeutic agents
GB201410815D0 (en) 2014-06-17 2014-07-30 Ucb Biopharma Sprl And Katholieke Universiteit Leuven Therapeutic agents
GB201410817D0 (en) 2014-06-17 2014-07-30 Ucb Biopharma Sprl And Katholieke Universiteit Leuven K U Leuven R & D Therapeutic agents

Also Published As

Publication number Publication date
CA3007975A1 (en) 2017-06-15
ES2894680T3 (es) 2022-02-15
WO2017097871A1 (en) 2017-06-15
EP3386984B1 (en) 2021-08-11
US10450320B2 (en) 2019-10-22
EA037559B1 (ru) 2021-04-14
CN108699064B (zh) 2021-09-14
EA201891349A1 (ru) 2019-01-31
CN108699064A (zh) 2018-10-23
EP3386984A1 (en) 2018-10-17
JP6775019B2 (ja) 2020-10-28
US20180362532A1 (en) 2018-12-20
JP2019502678A (ja) 2019-01-31
GB201521767D0 (en) 2016-01-27

Similar Documents

Publication Publication Date Title
CL2017002123A1 (es) Heterociclos biciclicos como inhibidores de fgnr
BR112016029630A2 (pt) derivados heteroaromáticos bicíclicos fundidos como inibidores de inibidores de cinase
CY1119588T1 (el) Εκλεκτικοι αναστολεις pi3κ δελτα
CL2016001968A1 (es) Proteinas de fusion de interleucina-2 y usos de las mismas
CO2017011851A2 (es) Compuestos novedosos
BR112018006135A2 (pt) derivados de pirazol fundidos como inibidores da cinase
BR112017024384A2 (pt) bactérias modificadas para reduzir hiperfenilalaninemia
BR112017017727A8 (pt) Heterociclos bicíclicos como inibidores de fgfr4
BR112016029632A2 (pt) derivados heteroaromáticos bicíclicos fundidos como inibidores de cinase
BR112019010222A8 (pt) Polimorfos de sepiapterina e sais dos mesmos
BR112016012990A2 (pt) Derivados de imidazol tricíclicos fundidos como moduladores de atividade de tnf
BR112016011483A2 (pt) Derivados de imidazotriazina como moduladores de atividade de tnf
BR112016011484A2 (pt) Derivados de imidazopirimidina como moduladores de atividade de tnf
BR112016011792A2 (pt) Derivados de imidazopiridina como moduladores de atividade de tnf
UY36265A (es) “derivados de pirrolo[2,3-d]pirimidina”.
BR112016011485A2 (pt) Derivados de imidazopiridazina como moduladores de atividade de tnf
MX2015006859A (es) Anticuerpos anti-vegf y sus usos.
GEP20227382B (en) Anti-coagulation factor xi antibodies
BR112016029635A2 (pt) derivados pirazolo-piridina como inibidores de quinase
CO7111276A2 (es) Compuestos de 3,5 disustituido-3h imidazo[4,5-b] piridina y 3,5 disustituido - 3h-[1,2,3] triaolo [4,5-b] piridina novedosos como moduladores d proteínas cinasas c-met
EA201500654A1 (ru) Терапевтически активные производные пиразолопиримидина
CY1121933T1 (el) Υποκατεστημενες δικυκλικες διυδροπυριμιδινονες και χρηση αυτων ως αναστολεις δραστικοτητας ελαστασης ουδετεροφιλου
CY1124492T1 (el) 7-υποκατεστημενα 1-αρυλο-ναφθυριδιν-3-καρβοξαμιδια και η χρηση αυτων
CO2017010621A2 (es) Compuestos bicíclicos fusionados para el tratamiento de enfermedades
CL2019000702A1 (es) Anticuerpos anti-gm-csf y usos de los mismos.

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]

Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS.

B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 6A ANUIDADE.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2700 DE 04-10-2022 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.